First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improve...( -- Major study of more than 2100...),Health

-- Major study of more than 2,100 patients with hip fracture shows significant 35% reduction in subsequent osteoporotic fractures with Reclast

-- Results published in The New England Journal of Medicine show significant 28% reduction in overall mortality seen in study patients

treated with Reclast -- Few patients currently receive osteoporosis treatments following hip

fracture despite high risk of morbidity and mortality (1)

-- Reclast, recently FDA approved for treatment of postmenopausal

osteoporosis, shown effective in reducing spine and hip fractures in

another study

EAST HANOVER, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Results of the first ever clinical study in osteoporosis patients who have had a hip fracture show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection reduced the risk of subsequent fractures by 35% compared to placebo.

This study found that the risk of death was significantly reduced by 28% in the Reclast group compared to the placebo group (101 versus 141 deaths, respectively). Osteoporosis patients with hip fractures may face devastating consequences, with almost a quarter of people over age 50 who suffer a hip fracture dying within one year (2). Among those who survive, 50% require assistance walking, 25% require long-term nursing care and all remain at high risk for fracture (3). Yet, few men and women with hip fractures are diagnosed and treated for osteoporosis following a hip fracture (1).

The landmark study, which included more than 2,100 men and women, was published online today as an early release article in The New England Journal of Medicine and presented simultaneously at the annual meeting of the American Society for Bone & Mineral Research (ASBMR).

"Experts agree that the serious consequences of osteoporosis can be prevented, yet the condition is often under-diagnosed and under-tre
'/>"/>